China's Innovent Biologics May Look Into M&As, CFO Says

The video discusses a biopharmaceutical company's journey from its establishment in 2011 to becoming a major player in the industry. It highlights the company's achievements, including the development of a fully integrated platform and successful commercialization of biological products. The discussion covers market competition, particularly in China, and the company's strategies for global expansion through collaborations with international giants like Eli Lilly. Financial strategies, including a recent $610 million share placement, are also discussed, along with future plans for product development and market penetration.

What are the prospects for the company in becoming a global biopharmaceutical player?

What recent approval did the company announce regarding lung cancer?

What are the future indications the company is looking forward to getting approved?